O-GlcNAcylation at T212 competes with phosphorylation to redirect pathological tau from ESCRT-dependent exosomal release
🧪 Overview
We hypothesize that pathological tau's abnormal interaction with the ESCRT machinery for exosomal release is driven by site-specific loss of O-GlcNAcylation at T212, which normally prevents phosphorylation at nearby sites (S214, S262) that enhance TSG101/ESCRT-I binding. In normal states, O-GlcNAcylation at T212 competes with these pro-aggregation phosphorylations, limiting tau's engagement with ESCRT components and preventing pathological secretion. In disease states, reduced O-GlcNAcytransferase (OGT) activity at neuronal synapses leads to T212 hypogalactosylation, allowing hyperphosphorylation and enhanced binding to TSG101 via the PTAP-like motif. We predict that pharmacological activation of OGT or direct O-GlcNAcylation mimetics at T212 will specifically redirect pathological tau toward lysosomal degradation rather than exosomal release, without affecting normal ESCRT-dependent processes like cytokinesis or receptor downregulation that require non-tau substrates. This approach exploits the substrate selectivity of OGT toward tau at this specific site to achieve selectivity.
🧬 Mechanism
Curated pathway from expert analysis
flowchart TD
A["OGT O-GlcNAcylation<br/>T212 Site"]
B["T212 Competition<br/>with Phosphorylation"]
C["ESCRT-Dependent<br/>Exosomal Release Redirection"]
D["Pathological Tau<br/>Compartmentalized Exit"]
E["Tau Propagation<br/>Reduced"]
F["OGT-T212 Axis as<br/>Exosomal Routing Target"]
A --> B
B --> C
C --> D
D --> E
E --> F
style A fill:#1a237e,stroke:#4fc3f7,color:#4fc3f7
style F fill:#1b5e20,stroke:#a5d6a7,color:#a5d6a7⚖️ Evidence
No linked papers recorded for this hypothesis yet.
🏥 Translation
🧬 3D Protein Structure — OGT
No curated PDB or AlphaFold mapping for OGT yet. Search RCSB →
🧠 GTEx v10 Brain ExpressionJSON
Median TPM across 13 brain regions for OGT from GTEx v10.
💉 Clinical Trials
No clinical trials data linked to this hypothesis yet.
No curated ClinVar variants loaded for this hypothesis.
Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.
No DepMap CRISPR Chronos data found for OGT.
Run python3 scripts/backfill_hypothesis_depmap.py to populate.
🏆 Tournament
🏆 Arenas / Elo
📊 Market Indicators
💾 Resource Usage
🔮 Predictions
| Prediction | Predicted | Observed | Status | Conf |
|---|---|---|---|---|
| IF pharmacological OGT activation or T212 O-GlcNAc mimetics are applied to dividing cells with active ESCRT machinery, THEN cytokinesis completion (binucleated cell frequency) and EGFR/transferrin rec | Binucleated cell percentage remains <3% (unchanged from baseline ±20%); EGFR degradation rate constant (k_degradation) remains within 0.02-0.04 min⁻¹; transferr | — no observation — | pending | 0.55 |
| IF pharmacological OGT activation (small molecule activator or O-GlcNAc mimetic peptide) is applied to human iPSC-derived neurons overexpressing pathological tau (P301L), THEN exosomal tau secretion w | Exosomal tau concentration in conditioned media will be reduced by ≥50% (ELISA); intracellular tau colocalization with lysosomal markers will increase by ≥2-fol | — no observation — | pending | 0.65 |
▸Metadatasource: v1_phase_c_backfill · origin_type: audit_hypothesis_generator
| source | v1_phase_c_backfill |
| origin_type | audit_hypothesis_generator |
| _schema_version | 1 |